PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.44%
R&D change of 0.44% versus flat Biotechnology spending. Walter Schloss would verify adequacy.
34.62%
G&A change of 34.62% versus flat Biotechnology overhead. Walter Schloss would verify efficiency.
No Data
No Data available this quarter, please select a different quarter.
-26.41%
Other expenses reduction while Biotechnology median is 0.00%. Seth Klarman would investigate advantages.
14.45%
Operating expenses change of 14.45% versus flat Biotechnology costs. Walter Schloss would verify control.
14.45%
Total costs change of 14.45% versus flat Biotechnology costs. Walter Schloss would verify control.
561.32%
Interest expense change of 561.32% versus flat Biotechnology costs. Walter Schloss would verify control.
-26.41%
D&A reduction while Biotechnology median is 0.00%. Seth Klarman would investigate efficiency.
55.40%
EBITDA change of 55.40% versus flat Biotechnology. Walter Schloss would verify quality.
No Data
No Data available this quarter, please select a different quarter.
-14.45%
Operating income decline while Biotechnology median is -0.80%. Seth Klarman would investigate causes.
No Data
No Data available this quarter, please select a different quarter.
231.19%
Other expenses change of 231.19% versus flat Biotechnology. Walter Schloss would verify control.
43.33%
Pre-tax income growth while Biotechnology declines. Peter Lynch would examine advantages.
No Data
No Data available this quarter, please select a different quarter.
561.32%
Tax expense change of 561.32% versus flat Biotechnology. Walter Schloss would verify strategy.
43.33%
Net income growth while Biotechnology declines. Peter Lynch would examine advantages.
No Data
No Data available this quarter, please select a different quarter.
43.35%
EPS change of 43.35% versus flat Biotechnology. Walter Schloss would verify quality.
43.35%
Diluted EPS change of 43.35% versus flat Biotechnology. Walter Schloss would verify quality.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.